Klichinsky et al. employed the THP-1 macrophage model cell line to express anti-CD19-, anti-meso-, and anti-HER2-CD3ζ CARs (CAR macrophages, CARMA) and showed them to selectively clear cognate antigen-bearing tumor cells, promote CTL proliferation, as well as to reduce tumor burden in an ovarian cancer xenograft model [89]. This evidence concerns the gene CD19 and neoplasm.